Cancer Diagnostics Market Size By Application, By Cancer Type, By End-use, Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023

Description

List of Tables

Cancer Diagnostics Market is anticipated to grow substantially through 2032, owing to the increasing awareness around cancer and rising healthcare expenditure for offering better and more innovative treatments. Growing chronic illnesses, high disposable incomes, and increasing infectious disease prevalence have resulted in the demand for pathological laboratories, positively influencing the cancer diagnostics industry outlook. Besides, the growing need to diagnose lump formation at nascent stages will as well add impetus to the cancer diagnostics demand.

Overall, the cancer diagnostics industry is segmented in terms of application, cancer, end-use, and region.

Based on application, the tumor biomarkers tests segment was valued at over USD 27.5 billion in 2022. The wide application of biomarkers in cancer treatment, drug development, and diagnostics is slated to impel the product demand through the coming years. Besides, biomarkers are crucial for every stage of the disease. Additionally, the effectiveness and affordability of tumor biomarker tests would stimulate the market growth curve over 2023-2032.

Considering the cancer, the breast cancer segment will register notable growth during the estimated timeframe. Increasing cases of breast cancer recorded worldwide due to unhealthy lifestyles, obesity, and reduced childbearing will bolster the segmental growth in the ensuing years. For the record, in 2022, an estimated 287,850 new cases of invasive and 51,400 new cases of non-invasive breast cancer were diagnosed in women in the U.S.

By end-use, the diagnostic laboratories segment is expected to depict more than 9.5% CAGR during the forecast timeframe. Diagnosis of a medical condition, precise readings, helping the doctor reach a conclusion, online reports, advanced equipment, and deliverance of instant results are some key factors slated to boost segmental expansion in the foreseeable future.

Regionally, the Asia Pacific cancer diagnostics market is expected to grow significantly from 2023 to 2032. The regional market growth can be attributed to the constantly surging tobacco and alcohol consumption. In addition, sedentary lifestyle and unhealthy eating habits will also serve as key factors leading to several types of cancers, owing to which there has been a rising demand for diagnostics services in developed economies. According to reliable reports, in 2020, the cancer prevalence in the APAC region was 169.1 per 1,00,000, which accounted for 49.3% of the cancer incidence globally.

Product Code: 2406

Chapter 1 Methodology

1.1 Methodology
1.2 Market scope & definitions
1.3 Base estimates & working
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
- 1.7.1 Secondary
  - 1.7.1.1 Paid sources
  - 1.7.1.2 Public sources
- 1.7.2 Primary

Chapter 2 Executive Summary

2.1 Cancer diagnostics industry 360 degree synopsis, 2018-2032
- 2.1.1 Business trends
- 2.1.2 Application trends
- 2.1.3 Cancer type rends
- 2.1.4 End-use trends
- 2.1.5 Regional trends

Chapter 3 Cancer Diagnostics Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2018 - 2032
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Rising prevalence of cancer globally
  - 3.3.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
  - 3.3.1.3 Growing number of diagnostic laboratories in developed countries
  - 3.3.1.4 Technology advancements in developed countries
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 High capital investment coupled with high costs associated with diagnostic imaging systems
  - 3.3.2.2 Risk related with high radiation exposure affecting use of CT scanner
3.4 Growth potential analysis
- 3.4.1 By application
- 3.4.2 By cancer type
- 3.4.3 By end-use
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
- 3.6.1 U.S.
- 3.6.2 Europe
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis
4.3 Strategic dashboard

Chapter 5 Cancer Diagnostics Market, By Application

5.1 Key application trends
5.2 Tumor biomarkers tests
- 5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Imaging
- 5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.2 Ultrasound and radiology
  - 5.3.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.3 Mammography
  - 5.3.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.4 MRI scan
  - 5.3.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.5 PET scan
  - 5.3.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.6 CT scan
  - 5.3.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.7 SPECT & others
  - 5.3.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.4 Biopsy
- 5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.5 Liquid biopsy
- 5.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.6 Immunohistochemistry
- 5.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.7 In situ hybridization
- 5.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 6 Cancer Diagnostics Market, By Cancer Type

6.1 Key cancer type trend
6.2 Bladder cancer
- 6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Breast cancer
- 6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Colon and rectal cancer
- 6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Endometrial cancer
- 6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.6 Kidney cancer
- 6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.7 Leukemia
- 6.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.8 Liver-lung cancer
- 6.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.9 Melanoma
- 6.9.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.10 Non-Hodgkin lymphoma
- 6.10.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.11 Pancreatic cancer
- 6.11.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.12 Prostate cancer
- 6.12.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.13 Thyroid cancer
- 6.13.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.14 Others
- 6.14.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 7 Cancer Diagnostics Market, By End-use

7.1 Key end-use trend
7.2 Hospitals
- 7.2.1 Market size, by region, 2018 - 2032 (USD Million)
7.3 Diagnostic laboratories
- 7.3.1 Market size, by region, 2018 - 2032 (USD Million)
7.4 Diagnostic imaging centers
- 7.4.1 Market size, by region, 2018 - 2032 (USD Million)
7.5 Cancer research institutes
- 7.5.1 Market size, by region, 2018 - 2032 (USD Million)

Chapter 8 Cancer Diagnostics Market, By Region

8.1 Key regional trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Russia
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 MEA
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE

Chapter 9 Company Profiles

9.1 Abbott Laboratories
9.2 AB Sciex Pte. Ltd
9.3 Agilent Technologies Inc
9.4 Becton, Dickinson and Company
9.5 Biocare Medical LLC
9.6 Biocartis
9.7 BioMerieux SA
9.8 Bio-Rad Laboratories
9.9 Cancer Genetics Inc
9.10 GE Healthcare
9.11 Hologic Inc
9.12 Janssen Diagnostics LLC (Johnson & Johnson)
9.13 Leica Biosystem Nussloch GmbH (Danaher Corporation)
9.14 Myriad Genetics, Inc
9.15 Qiagen N.V
9.16 F-Hoffmann-La Roche Ltd
9.17 Siemens Healthineers
9.18 Sysmex Corporation
9.19 Thermo Fischer Scientific